Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.04 USD
-0.33 (-13.92%)
Updated May 8, 2024 04:00 PM ET
After-Market: $2.05 +0.01 (0.49%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Brokerage Reports
Esperion Therapeutics, Inc. [ESPR]
Reports for Purchase
Showing records 1 - 20 ( 150 total )
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
BDA U.S. Label Expansion For CV Risk Reduction All Set; Look For EMA Approval in 2Q24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
BDA Ready, Set, Go for Label Expansions; March 31 PDUFA; Potential EMA Approval in 2Q24; Target to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Litigation Out, Cash In; Focus Solely On Timely E.U. Commercialization
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
FDA Taking Actions Ahead of CV Risk Reduction Label Expansions
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J